New drug MK-1045 takes on tough lymphomas
NCT ID NCT07519772
First seen Apr 10, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tests a new immunotherapy drug called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. The main goals are to check safety and see if the drug can shrink or eliminate tumors. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hospital ( Site 1701)
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-••••
-
Haddasah Medical Center ( Site 0600)
RECRUITINGJerusalem, 9112001, Israel
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0601)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation Trust ( Site 1300)
RECRUITINGManchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1045 (also called CN-201), an immunotherapy drug given by IV or injection
What this could lead to
If successful, MK-1045 could offer a new treatment option for people with certain types of non-Hodgkin lymphoma that have not responded to other therapies.
What could go wrong
This is an early-phase trial (1b/2) with only 200 participants, so results may not apply to everyone. Side effects are possible, and the drug may not shrink tumors in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.